Sign In
Buy FSTX
$7.12
+0 (+0%)
At Close: Jun 07, 2023
Study Published in Nature Shows F-Star's STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
09:27am, Monday, 19'th Apr 2021
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
09:22am, Saturday, 10'th Apr 2021
Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation Study Confirms F-star's Bispecific Antibody Tetravalency is the Most Eff
FSTX Stock Price Increased Over 5% Pre-Market: Why It Happened
09:07am, Tuesday, 30'th Mar 2021
The stock price of F-star Therapeutics, Inc. (NASDAQ: FSTX) increased by over 5% pre-market. This is why it happened.
FSTX Stock Price Increased Over 34% Intraday: Why It Happened
02:30pm, Thursday, 25'th Mar 2021
The stock price of F-Star Therapeutics Inc (NASDAQ: FSTX) has increased by over 34% during intraday trading. This is why it happened.
Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday
12:22pm, Thursday, 25'th Mar 2021
Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.
F-star Therapeutics to Present at Upcoming Investor Conferences
08:00am, Thursday, 04'th Mar 2021
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next gen
FSTX Stock Price Increases Over 25% Pre-Market: Why It Happened
08:24am, Monday, 01'st Mar 2021
The stock price of F-star Therapeutics, Inc. (NASDAQ:FSTX) has increased by over 25% pre-market. This is why it happened.
F-star Therapeutics: New Biologics Platform For Immunotherapy
11:00am, Thursday, 21'st Jan 2021
F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value.
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1
08:00am, Wednesday, 20'th Jan 2021
Patent protects Company's lead clinical asset FS118 throughout Europe Patent protects Company's lead clinical asset FS118 throughout Europe
F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
08:00am, Monday, 04'th Jan 2021
FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company's third bispecific to enter clinical trials
